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ABSTRACT
The use of high-dose interleukin-2 (IL-2) has fallen out of favor due to severe life-threatening side effects.
We have recently described a unique way of directly targeting IL-2 to cytotoxic lymphocytes using a virally
encoded immune evasion protein and an IL-2 mutant that avoids off-target side effects such as activation
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Systemic high-dose IL-2 as a curative form of
immunotherapy
High-dose interleukin-2 (IL-2) cytokine therapy was ﬁrst
approved by the FDA for treatment of advanced renal cell car-
cinoma (RCC) in 1992 and for advanced melanoma in 1998.
High-dose IL-2 activates and induces proliferation of natural
killer (NK) cells and CD8C cytotoxic T cells, leading to potent
anticancer activity, which results in a durable complete remis-
sion in up to 9% of RCC patients with a median durability of
70 mo. Many patients experience remission lasting more than
10 y.1 This rate is in contrast to the <1% complete remission
rate of the anti-PD1 therapy nivolumab, which received Food
and Drug Administration (FDA) fast-track approval. Despite
highly promising results, high-dose IL-2 therapy is rarely used
today because many patients experience severe adverse effects,
such as fever, malaise, and systemic capillary leak. As a result,
close to 50% of patients discontinue therapy, and a further 2–
5% of patients will die as a result of therapy-induced pulmo-
nary edema and cardiovascular instability.
These side effects are the result of off-target signaling via the IL-
2 receptor (IL-2R). Cytotoxic lymphocytes (CTLs) express the low-
afﬁnity IL-2Rbg form of the receptor at baseline but after initial
activation display the high-afﬁnity IL-2Rabg receptor that is ulti-
mately required for peak effector function. In contrast, vascular
endothelium expresses the high-afﬁnity IL-2Rabg receptor at
baseline and thus high-dose IL-2 results in inﬂammation, vascular
leakage, and the associated adverse events due to direct vascular
toxicity. Furthermore, CD4C Foxp3C Tregs also express the
high-afﬁnity IL-2Rabg receptor at baseline and are preferentially
activated by IL-2. Tregs normally function to downregulate immune
responses, and in the context of cancer immunotherapy limit the
therapeutic potential of the CTLs (Fig. 1A).
Alternative forms of IL-2 and IL-2 delivery
Previous investigators have hypothesized that a form of IL-2 that
prevents Treg activation could greatly enhance therapeutic efﬁcacy.
2
There are multiple described mutations that decrease IL-2 afﬁnity
for IL-2Ra, such as the substitution of alanine for arginine (R38A)
and lysine for phenylalanine (F42K).3 Alternately, antibody-bound
forms of IL-2 have been developed to reduce IL-2Ra binding.4
Unfortunately, IL-2Ra-inhibited therapies have reduced NK-cell
activation and a correspondingly reduced therapeutic index due to
the requirement of the high-afﬁnity receptor for peak cytotoxicity.
Another strategy has been to create mutants with increased afﬁnity
for IL-2Rb in an effort to remove the preference for IL-2Ra.5 The
IL-2Rb-enhanced IL-2mutants still bind and activate Tregs and vas-
cular endothelium and thus still have “off target” side effects. Sev-
eral groups have attempted to direct cytokine delivery to the tumor
bed or vasculature via a targeted antibody-IL-2 conjugate but these
therapies may be limited due to the ability of the tumor to escape
by shedding, mutating, or downregulating the targeted antigen.
Furthermore, the tumor-associated microenvironment actively
excludes lymphocytes, thus preventing CTLs from encountering
IL-2. Others have extended the half-life of IL-2 by conjugating it
with anti-IL-2 antibodies or stabilizing the cytokine in the blood
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stream through the addition of polyethyline glycol.6 None of these
approaches, however, signiﬁcantly ameliorates Treg activation with
unproven results in human trials.7
Unique method for IL-2 delivery to cytotoxic
lymphocytes as a superior form of immunotherapy
We have recently described a new form of IL-2 immunotherapy
through targeted delivery of an IL-2 mutant directly to CTLs.
We utilized a high-afﬁnity, virally encoded NKG2D ligand
known as orthopoxvirus major histocompatibility complex
class I like protein or OMCP8 (Fig. 1B). Since NKG2D is
expressed constitutively on murine NK cells as well as activated
murine CD8C T cells, the new OMCP-(R38A/F42K)IL-2 pro-
tein resulted in preferential binding to and activation of NK
cells over Tregs (Fig. 1B and C), improved immunotherapy
against both solid and hematopoietic tumors (Fig. 1D), and no
systemic capillary leak or animal mortality (Fig. 1E and F).
Figure 1. Targeted delivery of IL-2. (A) Proposed model of competition between NK cells and stromal cells for IL-2. (B) NKG2D targeted OMCP-mutIL-2 preferentially delivers
cytokine to NK cells. Width of arrow indicates proposed strength of IL-2 signaling. (C) In vitro ﬂow cytometrically evaluated activation of A/J spleen-derived lymphocyte subsets
after 36 h of culture in 100 IUe/mL of cytokines or OMCP-mutIL-2 construct. Graph demonstrating one representative histogram plot and median ﬂuorescent intensity (MFI) §
S.E.M. across 5–7 separate experiments. (D) Survival of C57BL/6 mice treated with 750,000 IUe of cytokine 5 d after injection of 1£105 LLC intravenously (E) ascites (representa-
tive syringe—left; average from all mice in the group—right) in A/J mice treated with 200,000 IUe of either wild-type IL-2 (blue) or OMCP-mutIL-2 (red). (F) Animal mortality
and morbidity, as assessed by survival (top) and weight loss (bottom) of A/J mice treated with supratherapeutic doses of wild-type IL-2 or OMCP-mutIL-2. NK cells were either
depleted with anti-asialo GM (solid line) or not (dashed line). (G) In order to compare antibody-mediated delivery of mutIL-2 we engineered four anti-human NKG2D single
chain variable fragment domains based on the described sequence of the KYK1 and KYK2 antibodies.11 1HL2 and 1LH2 are derived from the KYK1 antibody and 2HL2 and
2LH2 from the KYK2 antibody. The binding coefﬁcients of OMCP, KYK1, and KYK2 are 0.1 nM, 27 nM, and 6 nM, respectively. Similar to what is described for in vitro human
studies NK activation was measured by expression of intracellular perforin, whereas Treg activation by surface CD25 levels, both expressed as relative ration to saline control.
After 48 h in 100 U/mL NK cells treated with 2HL2 and 2LH2 antibodies synthesized as much perforin as OMCP-mutIL-2 treated cells but lower levels of perforin were evident
in 1HL2 and 1LH2 treated NK cells. Higher levels of CD25 were evident in wild-type IL-2 treated cultures over all constructs, p <0.05; p <0.001; ns D p > 0.05. Data from
Figure A-F modiﬁed from Ghasemi et. al., Nature Communications 2016; 7:12878; http://dx.doi.org/10.1038/ ncomms12878.
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Limited animal morbidity, manifest as weight loss, was
completely dependent on NK activation (Fig. 1F). OMCP offers
the highest known NKG2D binding afﬁnity of any known
ligand9,10 and has broad applications in both human and veteri-
nary immuno-oncology due to potential reactivity with multi-
ple species. Nevertheless, the use of anti-NKG2D antibodies to
target IL-2 to NK cells is also a possibility (Fig. 1G). Taken
together our work demonstrates the utility of targeted cytokine
delivery for the treatment of cancer immunotherapy and possi-
bly other forms of immune suppression.
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